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Measles Eradication:
Recommendations from a Meeting Cosponsored by
the World Health Organization, the Pan American
Health Organization, and CDC
Summary
Recent successes in interrupting indigenous transmission of measles virus in
the Americas and in the United Kingdom prompted the World Health Organiza-
tion (WHO), Pan American Health Organization (PAHO), and CDC to convene a
meeting in July, 1996 to consider the feasibility of global measles eradication.
Presentations at the meeting included an overview of global measles control
and elimination efforts; detailed reviews of successful measles elimination ef-
forts in Latin America, the English-speaking Caribbean, Canada, and the United
States; surveillance for clinical disease; laboratory tools for antibody detection
and virus identification; and other factors that might influence the feasibility of
disease eradication. With this background information, meeting organizers
asked participants to address five questions:
• Is global measles eradication feasible?
• Is measles eradication feasible with current vaccines?
• What are the appropriate vaccination strategies for measles eradication?
• How should surveillance for measles be carried out?
• What role should outbreak control play in the strategy to eliminate measles?
Participants agreed that measles eradication is technically feasible with avail-
able vaccines and recommended adoption of the goal of global eradication with
a target date during 2005-2010, with the proviso that measles eradication efforts
should not interfere with poliomyelitis eradication but should build on the
successes of the global Poliomyelitis Eradication Initiative. Although existing
vaccines are adequate for eradication, vaccination strategies that rely on admini-
stration of a single dose of vaccine are not. In the Americas, sustained
interruption of indigenous measles virus transmission has been achieved
through a three-tiered vaccination strategy that includes a) “catch-up” vaccina-
tion of all persons aged 1–14 years, regardless of disease history or vaccination
status; b) “keep-up” vaccination of  ≥90% of children in each successive birth
cohort at age 12 months; and c) “follow-up” campaigns designed to vaccinate
all persons within a specific age range whenever the number of susceptible per-
sons in the preschool-aged population approximates the size of a typical birth
cohort (in practice, every 3–5 years). In other regions, different strategies may
be optimal. 
Surveillance, a critical component of any strategy to eliminate or eradicate
measles, has two functions: to assess the effectiveness of the measles elimina-
tion strategy and to detect circulation of measles virus in a population.
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Systematic surveillance based on clinical diagnosis should be implemented
early in any measles elimination program. In countries attempting to eliminate
indigenous measles, all isolated cases of measles and at least one case in each
chain of transmission should be confirmed by laboratory tests. Specimens for
virus isolation (e.g., urine, nasopharyngeal swabs, or blood) should be collected
in conjunction with field investigations. Vaccination campaigns generally have
not proved to be effective responses to measles outbreaks. Outbreaks should be
treated as opportunities to reinforce surveillance and to identify measures to
prevent future outbreaks. 
The major obstacles to measles eradication are not technical but perceptual,
political, and financial. Measles is often mistakenly perceived as a mild illness.
This misperception, which is particularly prevalent in industrialized countries,
can inhibit the development of public and political support for the allocation
of resources required for an effective elimination effort. The disease burden im-
posed by measles should be documented, particularly in industrialized
countries, so that this information can be used to educate parents, medical prac-
titioners, public health workers, and political leaders about the benefits of
measles eradication.
INTRODUCTION
During the early 1980s, in the aftermath of smallpox eradication, some scientists
and public health officials urged consideration of a global effort to eradicate mea-
sles (1 ). During the mid-1980s, however, the high level of population immunity
required to interrupt measles virus transmission became clear, and the prospect
of measles eradication seemed to recede (2 ). As recently as 1993, a task force on dis-
ease eradication declared measles “not now eradicable”(3 ). The major obstacles to
eradication cited by the task force were the contagiousness of measles, the lack of a
vaccine that is effective among children aged <9 months (most of whom have mater-
nal antibody to measles that protects them from disease but which also inhibits the
immune response to the vaccine virus), and the incorrect perception that measles is a
mild illness.
Recent successes in implementing new approaches to control and eliminate mea-
sles virus transmission prompted the World Health Organization (WHO), the Pan
American Health Organization (PAHO), and CDC to convene a meeting July 9–10, 1996,
in Atlanta to reconsider the feasibility of global measles eradication. Among the par-
ticipants were representatives of the sponsoring organizations, representatives of
regions and countries that have implemented measles elimination activities, and per-
sons affiliated with WHO Regional Offices, local and state health departments in the
United States, and universities. During the meeting, presenters reviewed vaccination
strategies and achievements in measles control in the Caribbean and Latin America,
Canada, and the United States. 
In addition, representatives of Denmark, Kuwait, Mexico, South Africa, and the
United Kingdom described their recent efforts to control or eliminate measles trans-
mission. In each of these countries, intensification of efforts to control measles has
been followed by sustained declines in the number of reported cases. 
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Other presentations addressed surveillance for clinical disease and laboratory tools
for virus identification and antibody detection. Information was presented concerning
other factors that could potentially affect the feasibility of measles eradication (i.e.,
the possible existence of nonhuman reservoirs for the virus, the possibility of trans-
mission of measles from persons with asymptomatic measles infection, and the
possibility that vaccination-induced immunity to measles might wane with the pas-
sage of time).
Based on this information and on subsequent discussion, meeting participants
were asked to address five questions: 
• Is global measles eradication feasible?
• Is measles eradication feasible with current vaccines?
• What are the appropriate vaccination strategies for measles eradication?
• How should surveillance for measles be carried out?
• What role should outbreak control play in the strategy to eliminate measles?
Discussion of these questions formed the basis for the conclusions and recommenda-
tions of the meeting. The rapporteur prepared a draft of the conclusions and
recommendations that was distributed and discussed in the final session of the 2-day
meeting. The discussion and subsequent modification of the draft ensured that the
report would reflect both points of consensus and the sense of discussions
among participants.
Definitions of Measles Elimination and Eradication
To facilitate communication among participants, working definitions of two im-
portant terms were developed during the meeting. Measles elimination refers to inter-
ruption of transmission in a sizable geographic area in which vaccination would
nevertheless need to continue because of the continued threat of reintroduction of the
virus. Eradication, defined as the global interruption of measles transmission, repre-
sents the sum of successful elimination efforts in all countries. Once eradication is
achieved, vaccination could be stopped without risk for measles outbreaks.
BACKGROUND
This section a) describes the status of global measles control; b) summarizes
efforts to eliminate measles in Latin America, the English-speaking Caribbean, and
Canada; and c) describes progress toward measles elimination in the United States.
The summaries are based upon material presented at the meeting and have been
updated by the presenters.
Status of Global Measles Control
Since the inception of the World Health Organization’s Expanded Programme
on Immunization (EPI) in 1974, the numbers of cases and deaths attributed worldwide
to measles have declined substantially, from an estimated 100 million cases and
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5.8 million deaths in 1980 to an estimated 44 million cases and 1.1 million deaths in
1995. In 1974, only 5% of the world’s children aged 12–23 months had been vaccinated
against measles. By the mid-1980s, measles vaccination coverage among children
aged 12–23 months in developing countries had reached only 42%, largely because
of the lack of infrastructure for delivering vaccines and the perception that measles
was not a serious public health problem (4 ). From 1985 through 1990, however,
the number of measles cases reported worldwide declined by 56% as governments,
international agencies and other organizations provided the human and financial re-
sources needed to reach the global goal of 80% infant immunization coverage by the
year 1990 (WHO, unpublished data). 
Despite these achievements, measles remains one of the leading causes of child
mortality in developing countries, responsible for approximately 10% of all deaths
among children aged <5 years (5 ). These deaths typically occur among young chil-
dren in countries with low vaccination coverage levels. Even countries that have
achieved high levels of measles vaccination coverage and have recorded several
years of low incidence frequently have experienced large measles outbreaks (6–9 ).
On the basis of vaccination coverage, case fatality rates, and vaccine effectiveness,
WHO estimates that by 1995 measles-associated morbidity and mortality had de-
creased by 78% and 88%, respectively, in comparison with the pre-vaccine era (WHO,
unpublished data).
Although these estimates demonstrate a marked reduction in the health burden of
measles, they also indicate that the mid-decade goals of reducing measles morbidity
by 90% and measles mortality by 95% have not been met. Measles outbreaks have
continued to occur because, even in countries with high vaccination coverage, the
proportion of children susceptible to the disease increases over time and eventually
reaches a level that sustains measles transmission. Ongoing measles outbreaks have
been particularly problematic in developing countries. Low vaccination coverage has
been primarily responsible for these outbreaks. However, the practice of vaccinating
children aged <12 months has also contributed because the vaccine is less effective
among children of this age. (Vaccinating of children aged <12 months has also sub-
stantially reduced measles incidence in this age group, in which mortality from the
disease is highest.) Compared with vaccinating children aged ≥12 months, vaccinating
those younger than 12 months hastens the accumulation of susceptible persons in the
preschool-aged population. 
In some developing countries, two-dose measles vaccination schedules were intro-
duced to slow the increase of susceptible children by vaccinating those who had
missed the first dose and providing protection to those who did not develop an
immune response after a single dose of measles vaccine. This strategy has inter-
rupted measles transmission in some industrialized countries that have achieved
vaccination coverage levels exceeding 95% for both doses of vaccine. Attainment of
such high coverage levels required active follow-up of children who missed a sched-
uled dose (10 ). In developing countries, outbreaks have continued to occur after
two-dose schedules were implemented, because the second dose (scheduled at ages
ranging from 18 months to primary- or secondary school entry) seldom reached pre-
viously unvaccinated children, and coverage attained with the second dose is always
lower than with the first dose (11 ).
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Since 1994, a strategy of limited vaccination campaigns targeting all children aged
9 months to 5 years has been advocated to reduce measles morbidity and mortality
by reaching unvaccinated children in areas in which risk for measles is high (e.g.,
large, densely populated urban and peri-urban centers)(12 ). This strategy is intended
to improve vaccination coverage and not necessarily to interrupt measles virus trans-
mission. Several countries in WHO’s Southeast Asian Region (i.e., Bangladesh, India,
Myanmar, and Nepal), and its Western Pacific Region (i.e., the Philippines) have
used the strategy with only modest success. Many children who were unvaccinated
before the campaigns remained unvaccinated afterward. In addition, poor case sur-
veillance hindered efforts to evaluate the impact of the campaigns in reducing the
disease burden. 
The experience in the Philippines provides an example of these difficulties. Imme-
diately after a measles vaccination campaign that targeted urban areas in that country,
a measles epidemic occurred. The epidemic prompted a vaccination coverage survey,
which indicated that the campaign had succeeded in vaccinating only 44% of pre-
viously unvaccinated children (Philippine Ministry of Health, unpublished data).
Although vaccination campaigns limited to high-risk areas can help reduce morbidity
and mortality caused by measles, they do not result in the sustained interruption of
measles virus transmission. Such campaigns must include provisions for vaccinating
previously unvaccinated children and improving surveillance so that the impact of the
campaign can be measured.
The impact of measles vaccination has varied substantially among the six WHO
Regions (Figure 1). These interregional differences reflect disparities in routine immu-
nization coverage levels and, more importantly, in the effectiveness of different






























































































































































































FIGURE 1. Reported incidence of measles — World Health Organization regions,
1990–1995
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measles control has been achieved in the Americas, where most countries have
implemented a strategy based on a one-time-only mass vaccination campaign across
a wide age group. The goals of this strategy are to achieve a rapid reduction in the
number of susceptible children in the population and to interrupt the transmission of
measles virus. To keep the susceptible population from exceeding the epidemic
threshold requires high routine coverage and periodic “follow-up” campaigns to vac-
cinate children born after the previous campaigns. A strategy similar to that used in
the Americas has been implemented or is being considered in at least one country in
each of the other WHO regions. For example, mass campaigns that included children
aged ≤16 years have been conducted in the United Kingdom in the European Region,
Bhutan and Mongolia in the Western Pacific Region, Kuwait and Oman in the Eastern
Mediterranean Region, and South Africa in the African Region.
Measles Elimination in Latin America, the English-Speaking
Caribbean, and Canada
After the eradication of wild poliovirus from the Americas was certified in 1994, the
ministers of health of the countries of the region established the goal of eliminating
measles virus circulation in the Western Hemisphere by the year 2000 (13 ). To achieve
this goal, PAHO has developed a measles elimination strategy (14 ) that shares certain
features with the successful poliomyelitis eradication strategy being implemented
throughout the world (15 ). In addition to careful measles surveillance, the PAHO
measles elimination strategy has three main components. First, a one-time-only
“catch-up” measles vaccination campaign is conducted, targeting all children aged
9 months through 14 years without regard to previous history of measles disease or
vaccination. The goal is to interrupt measles virus circulation rapidly by achieving
high levels of measles immunity across a wide age cohort. Early in the implementa-
tion of the PAHO measles eradication strategy, some “catch-up” vaccination
campaigns targeted only children who lacked documentation of measles vaccination.
For several reasons, these campaigns were less successful than later “nonselective”
campaigns that targeted all children without regard to disease history or vaccination
status. Problems identified in the early “selective” campaigns included difficulties in
determining the vaccination status of children and failure to vaccinate the small pro-
portion of children who remained susceptible to the disease after receiving a previous
dose of measles vaccine. 
After a “catch-up” campaign, efforts are directed at strengthening routine vaccina-
tion services for infants to slow the accumulation of susceptible preschool-aged
children and to maintain the interruption of measles virus circulation. This component
of the strategy is referred to as “keep-up” vaccination. Because interruption of
measles virus transmission reduces an infant’s risk for exposure to measles, the rec-
ommended age of routine measles vaccination can be safely increased from 9 months
to 12 months. The concomitant increase in measles vaccine efficacy reduces the per-
centage of vaccinated children who remain susceptible to the disease (16 ). Efforts are
made to achieve at least 90% coverage in each successive birth cohort in every district
of every country.
Because measles vaccine is <100% effective and universal vaccination coverage
is rarely achieved, the number of susceptible infants and children inevitably increases
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over time, thus increasing the risk for a measles outbreak if the virus is reintroduced.
To reduce the number of susceptible preschool-aged children, periodic “follow-up”
vaccination campaigns are conducted that target all children aged 1–4 years, regard-
less of vaccination status or disease history. These campaigns are designed to protect
susceptible children from measles, whether they are susceptible because they were
not vaccinated or because they did not develop a protective immune response to pre-
vious vaccination. The vaccination coverage obtained through routine vaccination
services dictates the interval between “follow-up” campaigns, which are conducted
when the estimated number of susceptible preschool-aged children approaches the
number of infants in an average birth cohort (in practice, every 3–5 years).
The first “catch-up” campaign in the Americas was conducted during 1987 in Cuba;
98% coverage with measles-mumps-rubella (MMR) vaccine was achieved in the popu-
lation aged 9 months to 14 years. In 1991, all countries of the English-speaking
Caribbean conducted a “catch-up” campaign with either single-antigen measles vac-
cine or MMR vaccine. Vaccination coverage exceeded 90%. By the end of 1995, all
countries of Latin America also had conducted “catch-up” campaigns. The estimated
measles vaccination coverage for children aged 1–14 years in the countries of Latin
America and the English-speaking Caribbean exceeded 93%.
Since 1994, “follow-up” campaigns have been conducted in Belize, Brazil, Chile,
Colombia, Costa Rica, Cuba, El Salvador, Guatemala, Jamaica, Nicaragua, Panama,
and Peru (17 ). The remaining countries in Latin America and the Caribbean are plan-
ning to conduct similar campaigns by the end of 1998.
To monitor progress toward measles elimination in the Americas, efforts have been
made to strengthen measles surveillance in every country. The goal of the PAHO mea-
sles surveillance system is rapid detection of measles virus circulation. In Latin
America and the Caribbean, >20,000 health units report weekly on the presence or
absence of suspected measles cases in their jurisdictions. At least one reporting unit
operates in every district or municipio (municipality) in every country of Latin America
and the Caribbean.
For surveillance purposes, any patient in whom a clinician suspects measles virus
infection is considered to have a suspected case of measles. Health-care workers
are requested to report all suspected cases immediately to local health authorities. To
determine whether suspected measles cases are actually caused by measles infection,
field epidemiologists attempt to investigate every reported suspected case in a
timely manner. Collecting a serum sample for laboratory analysis is an essential part
of such investigations.
Because other pathogens and conditions can produce clinical findings that resem-
ble measles, only laboratory investigation can provide the information needed to
confirm or discard suspected measles cases. Health-care workers are asked to collect
a single serum specimen from every patient suspected to have measles at the time
this presumptive diagnosis is made. In state or national laboratories, serum speci-
mens are tested with an enzyme immunoassay (EIA) for the presence of measles IgM
antibodies (14 ). Specimens are screened initially with a commercial indirect IgM mea-
sles assay that is sensitive but nonspecific. All specimens that are positive or
indeterminate by the indirect assay, as well as a 10% random sample of negative sera,
are sent to one of 11 regional reference laboratories in the PAHO measles laboratory
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network for confirmatory testing with the more specific IgM-capture EIA developed
by CDC (18 ). 
A suspected measles case is classified as laboratory-confirmed if both the indirect
and capture EIAs indicate the presence of measles IgM antibodies in a properly
collected serum specimen or if there is an epidemiologic link to another laboratory-
confirmed measles case. An epidemiologic link is defined as exposure to a person
with a previous or subsequent laboratory-confirmed case of measles. A suspected
measles case can be discarded only if a properly collected serum sample tests
negative for the presence of measles IgM antibodies. The case is classified as clinically
confirmed if a) no serum specimen is collected from a patient who has a suspected
case, and b) the case investigation does not reveal an epidemiologic link to a
laboratory-confirmed measles case. Such clinically confirmed cases are considered to
represent failures of the measles surveillance system, because the epidemiologic
investigation was not properly conducted.
In addition, PAHO has developed surveillance indicators to measure the effective-
ness and quality of national measles surveillance systems. These indicators include
the proportions of: 
• surveillance sites reporting to the national level each week, 
• suspected cases investigated within 48 hours after notification, 
• suspected cases completely investigated, including collection of an adequate se-
rum specimen, 
• cases confirmed by laboratory findings (versus clinically confirmed), 
• laboratory-confirmed cases with known source of infection, and
• specimens for which laboratory results are available within 7 days of receipt in
the laboratory. 
As experience accumulates, these indicators may be modified if the process of assess-
ing surveillance can be simplified without discarding information needed to improve
national measles surveillance systems.
After the 1977 initiation of the EPI in the Americas, measles vaccination coverage
increased steadily, measles incidence declined, and the intervals between measles
epidemics lengthened. However, a regionwide measles epidemic occurred in 1990,
when 218,000 measles cases were reported in Latin America and the Caribbean.
During this measles epidemic, the number of cases reported approached the number
reported in 1977. The “catch-up” measles vaccination campaigns, conducted in Cuba
in 1987 and in other Caribbean and Latin American countries during 1991–1994, imme-
diately reduced the number of reported measles cases (Figure 2). During 1995,
13,340 suspected measles cases were reported from Latin American and Caribbean
countries (Table 1). Of these, 9,517 (71.3%) were discarded because IgM serology
results were negative, 441 cases (3.3%) were confirmed by positive measles IgM labo-
ratory results, and 3,382 cases (25.3%) were classified as clinically confirmed because
of an incomplete epidemiologic investigation.
The total of 3,823 confirmed measles cases reported during 1995 from Latin Amer-
ica and Caribbean countries constitutes the lowest annual total ever reported for
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the region and represents a reduction of >98% compared with the number reported
in 1990. Measles is now rare in Latin America and the Caribbean. Surveillance
evaluations conducted during 1995 and 1996 in El Salvador, Mexico, and Nicaragua
found no evidence of measles virus circulation. During 1996, a provisional total of
864 confirmed measles cases was reported for Latin America and the Caribbean. Of
the total, 70 (8.1%) were confirmed by positive serologic tests for measles IgM anti-
body. The remaining cases were classified as clinically confirmed because laboratory
investigations were not conducted.
The last laboratory-confirmed case of measles detected in the English-speaking
Caribbean was reported in 1991, just before the mass vaccination campaign was
conducted. Similarly, the last laboratory-confirmed cases of measles in Cuba and
Chile were detected in 1993. In other Latin American and Caribbean countries,
measles transmission is occurring at extremely low levels, if at all. Most laboratory-
confirmed cases have been sporadic and isolated in time and place.
Importations of measles cases from Latin America detected by the United States
measles surveillance system provide an indirect measure of the impact of the PAHO
measles elimination strategy (Figure 3). In 1990, >200 cases, or >80% of all cases of
measles imported to the United States, came from Latin America (principally Mexico).
Since then, the number and proportion of measles cases imported from Latin America
have declined markedly. The last laboratory-confirmed case of measles imported from
Latin America or the Caribbean to the United States was reported in 1994.
Canada accounts for only 4% of the population of the Americas. In 1995, however,
Canada reported 2,362 measles cases, or nearly 40% of all measles cases reported
in the Western Hemisphere during that year. The routine measles vaccination sched-
ule introduced in the mid-1960s (i.e., a single dose of measles-containing vaccine
administered to children at age 12 months) had resulted in a 95% reduction in mea-
sles incidence, but did not interrupt measles virus transmission. Although Canada
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FIGURE 2. Annually reported measles cases — Latin American and Caribbean
countries, 1974–1996
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TABLE 1. Final classification of reported suspected measles cases — Latin American
and Caribbean countries, 1995
Country












Argentina  1,808 1,153   651   4   655     134
Bolivia    92    16    76   0    76   1,441
Brazil  3,533 2,740   780  13   793      35
Chile    300   300     0   0     0       0
Colombia  2,530 2,120   204 206   410     525
Ecuador    919 —   919 —   919   3,668
Peru    636   283   224 129   353     670
Paraguay    142    69    69   4    73     122
Uruguay      5     0     5   0     5       0




Mexico  1,395 1,151   232  12   244      12
Belize     10     6     4   0     4       0
Costa Rica    251   216    32   3    35       0
El Salvador    260   260     0   0     0       0
Guatemala     56    33     0  23    23     204
Honduras     26    26     0   0     0       3
Nicaragua    195   190     5   0     5       3
Panama     92    73    16   3    19
      3
Caribbean
Anguilla      2     2     0   0    0       0
Antigua      1     1     0   0    0       0
Bahamas     11    11     0   0    0       0
Barbados     27    27     0   0    0       0
Cayman Isl.      0     0     0   0    0       0
Cuba     74    73     1   0    1       0
Dominica     37    37     0   0    0       0
Cuba     74    73     1   0    1       0
Dominican
Republic     32    32     0   0    0       3
Grenada      5     2     3   0    3       0
Fr. Guiana     —    —    —  —   —      —
Guadeloupe      0     0     0   0    0       0
Guyana     16    16     0   0    0       0
Haiti     —    —    —  —   —      —
Jamaica    133   118    15   0   15       0
Martinique     —    —    —  —   —       1
Montserrat      1     1     0   0    0       0
Netherlands
Antilles     —    —    —  —   —      —
Puerto Rico     11     0    —  11   11      13
St. Kitts & Nevis      2     1     1   0    1       0
St. Lucia      8     6     2   0    2       0
St. Vincent      0     0     0   0    0       0
Surinam     12    12     0   0    0       0
Trinidad & Tobago     57    57     0   0    0       0
Turks & Caicos      9     5     4   0    4       0
Br. Virgin Islands      1     1     0   0    0       0
U.S. Virgin Islands      0     0     0   0    0
      0
TOTAL 13,340 9,517 3,382 441 3,823 22,317
— No information provided.
 * Clinical suspicion of measles without laboratory investigation.
† Includes epidemiologically linked cases.
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consistently reached coverage levels of ≥97% with a single dose of measles-
containing vaccine among children aged 2 years, measles outbreaks continued to
occur, mostly among school-aged children. Outbreaks occurred even in populations
with documented vaccination rates approaching 100%. Control measures such as ex-
clusion from school and emergency mass revaccination proved disruptive, costly, and
of limited effectiveness. Although in 1992 a National Conference on Measles Control
had endorsed the goal of eliminating indigenous measles from Canada by 2005, little
progress had been made by 1995. Competing developments in childhood vaccination
programs preempted the formal introduction of a two-dose measles vaccination pro-
gram in Canada. The numbers of cases in Canada in 1995 contrasted with numbers
reported from other countries in the Americas and prompted the adoption of a na-
tional goal of measles elimination—with the needed political support—in late 1995.
Several analyses clarified the benefits of efforts to achieve the elimination of mea-
sles in Canada. Mathematical modeling and a Delphi survey predicted that there were
enough susceptible persons in the Canadian population to produce an annual average
of 12,800 measles cases. An outbreak involving ≥20,000 measles cases, 2,000 cases
with complications, and several measles-related deaths was predicted to occur
as early as April 1996 unless additional strategies to eliminate measles were imple-
mented. Mathematical modeling also predicted that phasing in a two-dose vac-
cination schedule by administering a second dose only to young children would
not eliminate measles for 10–15 years and that a national “catch-up” campaign was
the only way to avoid the predicted epidemic and prevent an estimated 58,530 cases































FIGURE 3. Measles cases imported from Latin American and Caribbean countries
into the United States, 1986–1996
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during the next several years. A cost-benefit analysis indicated that a measles vacci-
nation campaign would save more than 2.5 dollars for every dollar expended
(Laboratory Centre for Disease Control, Ottawa, unpublished data).
In late 1995, the National Advisory Committee on Immunization recommended a
mass measles vaccination campaign. By July 1996, six provinces (comprising 80% of
Canada’s population) had completed “catch-up” vaccination campaigns for all school-
aged children: in some provinces this included children aged ≥18 months, as well. Two
additional provinces began implementation of a “catch-up” program in the fall of
1996. More than 4 million children received supplementary vaccinations and provin-
cial coverage for the target populations averaged approximately 90%. Furthermore, all
of Canada’s provinces or territories have introduced a second MMR vaccination for
children aged 18 months or 4–6 years, depending on the province. 
These successful vaccination campaigns produced immediate results: three
measles outbreaks that had begun in early 1996 were quickly terminated as the cam-
paigns began. Only 324 cases of measles were reported in Canada for 1996; most of
these cases occurred before May, usually the month when incidence is highest. Trans-
mission of measles virus appears to have been interrupted during fall, 1996. The same
strategies should be implemented in the remaining provinces to ensure the sustained
interruption of measles virus transmission because of the continuing problem of mea-
sles importations from countries where measles transmission continues.
Measles Elimination in the United States
The United States is in the midst of a third attempt to eliminate indigenous trans-
mission of measles. Earlier efforts, initiated in 1966 and 1978, suppressed measles
incidence to levels below any previously recorded; 1,497 cases were reported in 1983,
the fewest in any year before the 1990s. Implementation of state requirements for
vaccination with measles-containing vaccine as a condition for school entry was one
of the major factors in increasing vaccination coverage and reducing the incidence of
measles (19 ). Low levels of measles transmission persisted through the mid-1980s.
An average of 2,900 cases was reported each year during 1983–1988. However, during
1989–1991, the United States experienced a resurgence of measles, during which
55,622 cases were reported. The largest increase in incidence occurred among pre-
school-aged children. Most cases occurred among children who had not been
vaccinated. This increase in measles cases prompted a major effort to ensure vaccina-
tion against measles at the recommended age. In 1994, the Childhood Immunization
Initiative established specific goals for vaccination coverage and disease reduction
(20 ). For measles, the goal for first-dose coverage was 90% by 1996 and the elimina-
tion of indigenous measles by 1996. These goals have largely been achieved.
Before the measles resurgence during 1989–1991, measles vaccination coverage
levels among children aged 2 years had never reached 70% (21 ). Since 1991, cover-
age levels with measles-containing vaccine have increased to 91% (22 ). These
improvements in coverage have been achieved through locally initiated efforts (e.g.,
linking immunization services with the Special Supplemental Nutrition Program for
Woman, Infants, and Children (WIC) and a program that coupled assessment of cover-
age levels among providers with feedback) (23–24 ). 
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In 1989, the Advisory Committee on Immunization Practices and the American
Academy of Pediatrics recommended that children in the United States receive two
doses of measles-containing vaccine. This recommendation was made to prevent out-
breaks in schools; several well-documented outbreaks demonstrated that measles
transmission could occur even with coverage levels >95% for a single dose of measles
vaccine (25–27 ). States have gradually implemented requirements that mandate a
second dose of measles-containing vaccine as a condition for entering school. For the
1996–97 school year, 35% of school-age children in the United States were covered by
such requirements (CDC, unpublished data). Records of doses of MMR vaccine pur-
chased and administered suggest that as many as 65% of school-age children have
received a second dose of measles-containing vaccine (CDC, unpublished data).
As a result of these efforts, a sustained decline in measles incidence occurred in the
United States beginning in 1993, when 312 confirmed measles cases were reported.
The reported number of cases increased to 963 in 1994; outbreaks among members of
groups that oppose vaccination were largely responsible for the increase. In 1995, a
total of 309 cases was reported, the fewest since national surveillance began. 
In addition to the decline in reported cases, epidemiologic evidence suggests that












































































































































































































































































































































































































FIGURE 4. Countries of origin and genotypes of measles virus isolated in the United
States, 1996
? indicates country of origin unknown.
Numerals indicate genotype group.
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December 31, 1993, 25 confirmed cases of measles were reported. Of these, seven
cases were classified as imported and 14 as importation-associated cases (i.e., cases
linked to a chain of transmission originating with an imported case). The four cases
classified as indigenous were not clustered geographically or temporally. They
occurred in widely separated geographic locations—California, Florida, upstate New
York, and Rhode Island. These cases were also widely separated in time—periods of
4 weeks and 6 weeks occurred during which no indigenous cases were identified.
These data suggest that the four indigenous cases (if they were, in fact, measles and
not some other illness misclassified because of false-positive laboratory test results)
more likely resulted from exposure to undetected imported cases than from ongoing
indigenous transmission of measles virus.
Molecular epidemiologic studies of wild-type measles virus also indicate that
indigenous measles transmission was interrupted during 1993. Measles viruses iso-
lated from throughout the United States during 1988–1993 were similar, suggesting a
single predominant lineage (28 ). Since 1993, that lineage has not been detected in the
United States, except in one case imported from the Philippines. Numerous wild-type
measles viruses isolated since 1993 have been similar to strains circulating outside
the United States. Strains similar to those found in Western Europe and East Asia
were particularly common in 1996 (Figure 4).
During October and November 1995, a 6-week period occurred during which all
cases of measles reported in the United States were either imported or linked to an
imported case. A similar 4-week period was observed during February 1996. During
late 1996 and early 1997, a 16-week period occurred when a single indigenous case
was identified. These data suggest that indigenous measles transmission in the
United States has been interrupted numerous times and that, in each instance, trans-
mission of the disease has been re-established by an importation of measles virus.
Since 1992, imported cases have made up an increasing proportion of all measles
cases reported in the United States. The number of imported cases detected has
declined from an average of 120 per year during 1985–1992 to 53 per year since 1993.
This reduction is almost entirely the result of decreases in imported cases from Latin
America (Figure 3). Since 1994, only one case that could possibly have been imported
from a Latin American country has been reported, and subsequent investigation re-
vealed no evidence of measles transmission in that country. Since 1992, most measles
cases imported to the United States have originated in Western Europe and East Asia,
reflecting relatively poor control of measles in these regions and frequent travel to the
United States. 
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CONCLUSIONS AND RECOMMENDATIONS
The five questions posed to meeting participants ( see Introduction) were designed
to structure discussion of the feasiblity of and strategies for measles eradication. The
conclusions and recommendations developed by participants in response to these
questions follow.
Feasibility of Measles Eradication
 Conclusions: 
Based on the success of efforts to control measles in the Western Hemisphere and
the United Kingdom, global measles eradication is technically feasible with available
vaccines. National, subregional, and regional elimination of measles can and should
be accomplished. Although nonhuman primates can be infected with measles virus,
such nonhuman reservoirs are unlikely to sustain measles transmission. Although
asymptomatic and nonclassical cases of measles can occur among vaccinated per-
sons, these atypical cases would not impede elimination or eradication of the virus.
Waning immunity does not appear to play a major role in vaccine failure. 
 Recommendations: 
A goal of global measles eradication should be established, with a target date dur-
ing 2005–2010. Factors that favor a global initiative to eradicate measles within this
time frame include:
• the expected success of poliomyelitis eradication by 2000,
• the success of measles elimination campaigns in the Americas and the United
Kingdom,
• the urgency of measles eradication because of expected epidemiologic changes
resulting from routine measles vaccination programs (i.e., the accumulation of a
growing population of susceptible adults), 
• the predicted favorable benefit-cost ratio, and 
• the recognition of measles as a major public health problem in many developing
countries. 
Although measles eradication is a logical addition to and extension of the polio-
myelitis eradication initiative, the effort should build on the success of poliomyelitis
eradication. Consequently, measles eradication should not be undertaken immedi-
ately and simultaneously in all parts of the world. Rather, measles eradication efforts
should await maturation of the poliomyelitis eradication program in each region of the
globe, and should be implemented as countries and regions become free of polio-
myelitis. Because of the rapid accumulation of persons susceptible to measles, the
implementation phase of an eradication effort should be compressed into as brief a
time as possible. Research into the molecular pathogenesis of measles and the
immune response to measles virus infection should continue.
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Vaccination Strategies 
 Conclusions: 
Existing vaccines are sufficient to eradicate measles, but eradication requires more
than a routine one-dose vaccination strategy. However, no single two-dose approach
is optimal for all countries. Success has been attained in many countries, particularly
in the Americas, with a strategy comprising a) “catch-up” mass campaigns during
which all persons aged 1–14 years are vaccinated, regardless of prior vaccination
status; b) high routine (“keep up”) vaccination coverage following the “catch-up”
campaign; and c) periodic “follow-up” campaigns during which all children aged
1–4 years are vaccinated. In some countries with highly developed vaccination pro-
grams capable of reaching >95% coverage, an ongoing two-dose “plus” strategy
appears capable of eventually eliminating measles. (The “plus” refers to special sup-
plementary efforts to reach populations at high risk.) Regardless of the strategy
selected, monitoring the accumulation of susceptible persons within the population is
essential. Accumulation of susceptible persons occurs because a single dose of vac-
cine does not elicit a protective immune response in some children and because some
children are not vaccinated. Such monitoring permits appropriate action, in the form
of “follow-up” campaigns or special vaccination activities in areas at highest risk.
 Recommendations: 
Countries that adopt a strategy of measles elimination should implement some
form of “catch-up” vaccination rather than simply adding a second dose to the routine
vaccination schedule. All children must receive measles vaccine, and the “second
dose” should also reach those who missed the first dose; such children should be
vaccinated and should subsequently receive another dose. Exploration of alternative
methods of vaccine delivery, particularly jet injectors, and of alternative preparations
of the vaccine should continue. 
Surveillance Strategies 
 Conclusions:
Measles case surveillance is a critical component of any strategy to control mea-
sles, including strategies to eliminate or eradicate measles. The most important
functions of surveillance are to assess the effectiveness of the strategy and to detect
circulation of measles virus in a population, rather than to identify every case of mea-
sles infection (except during the final stages of eradication). Although a passive
system of surveillance for measles may be adequate in countries or regions where
health-care providers detect and report measles cases, active surveillance is required
in many circumstances (e.g., areas where notification of suspected cases is low, where
a confirmed case has been identified, where clusters of suspected cases have been
reported, or where a dense population of unvaccinated children exists). As more coun-
tries interrupt measles transmission, importation of measles virus will become more
prominent. Because determining the source of an imported case can be difficult,
the following classification scheme for confirmed measles cases may be useful:
indigenous; source unknown; imported (source known); and imported (source un-
known). Surveillance indicators are a useful means of evaluating the performance of
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surveillance systems but must be limited in number to be optimally effective. No ex-
ternal standard for determining the completeness of measles surveillance exists that
is equivalent to the rate of acute flaccid paralysis for poliomyelitis.
 Recommendations: 
Surveillance for individual measles cases should be implemented at an early stage
of the elimination program. Measles notification should be based on clinical suspicion
rather than rigid case definitions. Case definitions are important, however, during
investigation and classification of suspected cases. To establish the source of
imported measles cases, collaboration among countries can be facilitated by WHO
offices. Experience in using measles surveillance indicators is limited, and proposed
indicators may be modified based on accumulating experience.
Laboratory Strategies
 Conclusions: 
Laboratory confirmation of suspected measles cases will become increasingly
important as measles incidence declines and countries progress toward elimination.
Establishment of a functioning global network of reference diagnostic laboratories will
be a critical element in achieving global eradication. Development of a rapid field
diagnostic test would facilitate surveillance and case investigations. In addition to con-
firmation of cases, the laboratory has a vital role in characterizing measles virus
isolates to determine whether cases represent sustained indigenous transmission or
importations. The laboratory can also serve an important function in surveillance for
measles immunity because serologic measures may be useful in confirming the level
of protection estimated by vaccination coverage of a population.
 Recommendations: 
In countries attempting to eliminate measles, all isolated cases of measles and at
least one case from each chain of transmission should be confirmed by laboratory
tests. In addition to serum or saliva specimens for laboratory confirmation, specimens
for virus isolation should be collected within 7 days of rash onset in conjunction with
case investigations. Specimens that can be cultured for virus isolation include urine,
nasopharyngeal swabs, and blood. Reference laboratories with expertise in culturing
measles virus should perform virus isolation. Development of a rapid field diagnostic
test is the most urgent research need.
Response to Measles Outbreaks
 Conclusions: 
Preventing measles outbreaks is more effective than trying to contain them. Mass
vaccination campaigns undertaken in response to outbreaks are of limited usefulness
in most countries because such efforts are costly, disruptive, and often ineffective by
the time they are instituted. Careful investigation of all outbreaks, however, can gen-
erate data needed to obtain the political support required for an effective elimination
effort. In addition, outbreak investigations can help determine why transmission of
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measles occurred; such investigations will be critical to refining measles elimination
strategies as they are implemented.
 Recommendations: 
Measles outbreaks should be treated as opportunities to reinforce surveillance,
assess the health burden of continuing measles transmission, and identify appropri-
ate measures to prevent future outbreaks.
Obstacles to Eradication
 Conclusions: 
The major obstacles to measles eradication are perceptual, political, and financial.
The full health impact of measles is often underestimated. Measles is frequently per-
ceived as a minor illness of little consequence, particularly in industrialized countries.
This perception may make it difficult to develop the political support necessary to
carry out a successful global eradication effort. Strong support for measles eradica-
tion can be expected in many developing countries, where measles is recognized as a
major killer. Measles eradication will quickly pay for itself because of savings in vacci-
nations, hospitalizations, and deaths prevented.
 Recommendations: 
Parents, medical practitioners, and public health professionals —particularly those
in industrialized countries—must be educated about the global disease burden
imposed by measles. The disease burden of measles should be better documented
in more countries, especially in the developed world, to gain support for global
eradication.
DISCUSSION
This 2-day consultative meeting represents a landmark in the history of measles
control. The data presented demonstrated the feasibility of interrupting measles
transmission for prolonged periods over wide geographic areas. Recently developed
molecular tools allow researchers to distinguish indigenous from imported virus
strains. Data developed with these tools support the claim that transmission of indige-
nous strains of measles virus has been interrupted for substantial periods in the
Americas and in the United Kingdom. In addition, global experience has now demon-
strated that an important distinction must be made between the limited measles
vaccination campaigns that have targeted urban or poorly served areas in many coun-
tries and the strategy that has interrupted measles transmission in the Americas and
the United Kingdom. Limited campaigns targeted to underserved or high-risk popula-
tions may improve vaccination coverage, but they are not sufficient to interrupt
transmission of the virus. Countries should undertake such geographically limited
campaigns only as part of a larger measles control or elimination strategy.
Presentations from representatives of individual countries and WHO regions docu-
mented the political and public interest in the eradication of measles, particularly
among developing countries. However, global consensus and commitment are essen-
tial because measles eradication will require supplementary vaccination activities in
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industrialized countries as well as in developing countries. In countries and regions
where endemic poliovirus transmission continues, poliomyelitis eradication efforts
must be further strengthened to ensure that the introduction of measles elimination
activities builds on the successes of the global poliomyelitis eradication initiative. A
global plan of action for the eradication of measles is needed to facilitate coordination
among countries, donors, technical agencies, and international organizations and to
ensure that eradication activities are conducted efficiently.
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